More Lawsuits Join Actos Bladder Cancer MDL

Allegedly, each of these plaintiffs or their loved ones developed Actos bladder cancer after taking the medication to treat their type-2 diabetes. Some of the plaintiffs that have joined the Actos MDL include:

• Elizabeth Rose Berry: Texas plaintiff who was prescribed Actos between December 2010 and August 2011. 
• Joan Marian Bettinger: Michigan plaintiff who is suing Takeda Pharmaceuticals on behalf of her deceased husband, James Philip Bettinger, who was prescribed Actos from September 2009 to May 2012.

• George Blossey: Michigan plaintiff who was prescribed Actos between August 2000 and January 2006.
• Bernard Bollendorf: Pennsylvania plaintiff who was prescribed Actos between June 2006 and May 2010.
• Ramon Collado: North Carolina plaintiff who was prescribed Actos between June 2007 and September 2011.
• Gerald F. Cooper: Ohio plaintiff who was prescribed Actos from 2002 through December 2011.
• Carol Quinn: New Jersey plaintiff who is suing Takeda Pharmaceuticals on behalf of Norman D’Ambrosio, who was prescribed Actos between 2000 and 2007.
• James Lamar Daniel: Georgia plaintiff who was prescribed Actos between August 2004 and January 2010.
• Rudolph J. DiMillo: Maine plaintiff who had been prescribed Actos between April 2000 and September 2004.

According to their Actos lawsuits, Takeda made no effort to contact the plaintiffs, decedents or their physicians about this possibility of developing bladder cancer, nor were there any indications or warnings about this risk on the drug’s label. They are suing Takeda for negligence, false advertising, concealing information and misrepresenting a product. There are at least 25 plaintiffs currently involved in the Actos bladder cancer MDL.

Overview of Actos Complications

Actos was first approved by the U.S. Food & Drug Administration (FDA) in July 1999 as a type-2 diabetes treatment drug. This drug is a part of an insulin-sensitizing diabetes agent drug family, called thiazolidinediones (TZDs). In 2008, it was the tenth best-selling drug in the United States, and reached more than $4.2 billion in global sales in 2009. Despite its vast global success, concerns were raised by the FDA after it was discovered that Actos induced cancerous tumors in lab mice.  

After several studies, the FDA released a public statement on June 15, 2011 regarding the Actos side effects. The announcement essentially stated that Actos patients had a significantly higher chance of developing bladder cancer if they used the drug for one year or more. The FDA based this announcement on a year of incident reports and concluded that patients who took Actos for more than one year had at least a 40 percent increased risk of developing bladder cancer. 

The Actos MDL is In Re: Actos Products Liability Litigation, MDL No. 2299, in the U.S. District Court for the Western District of Louisiana.

File an Actos Lawsuit Today

If you believe that you or a loved one have been the victim of Actos bladder cancer development, you have legal options. Please visit the Actos Bladder Cancer Class Action Lawsuit Investigation. There, you can submit your claim for a free legal review and if it qualifies for legal action, a seasoned Actos lawyer will contact you for a free, no-obligation consultation. You will be guided through the litigation process at no out-of-pocket expenses or hidden fees. The bladder cancer attorneys working this investigation do not get paid until you do.